MarketPeel
Insider Trading Intelligence
RH

Rachel Humphrey

PYXS
DIRECTOR · PYXIS ONCOLOGY, INC. · CIK 0001579781
FILING MIX · LIFETIME73%/27%
BUYS
8
SELLS
3
TOTAL VALUE
$52.2K
COMPANIES
2
ACTIVE SINCE
Sep 2020
HOLDINGS NOW
105,867
AVG SELL PX
$1.03
TRADE KIND
SHOWING 11 / 11
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Rachel Humphrey, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+33.33%+9.05%+2.12%+6.93%+9.34%
14d3+0.00%+13.38%+5.97%+7.41%+8.14%
30d3+0.00%+17.03%+11.76%+5.26%+7.95%
60d3+0.00%+22.39%+13.62%+8.77%+11.16%
90d3+0.00%+20.08%+18.94%+1.13%+4.99%
180d3+0.00%+252.25%+25.41%+226.85%+209.61%
1y3+0.00%+73.16%+33.58%+39.59%+37.48%
2y3(3 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PYXS · 45,867 shares · as of Mar 24, 2026
059,055118,110177,165236,2202023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 8 buys / 3 sellsCOVERAGE · 23 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
45,86745,867Mar 24, 2026Mar 25, 2026View →
PYXS
PYXIS ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
13,896$1.03$14.4K81,309Apr 21, 2025Mar 25, 2026View →
PYXS
PYXIS ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
200$0.97$19495,205Apr 17, 2025Mar 25, 2026View →
PYXS
PYXIS ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
1,400$0.97$1.4K95,405Apr 14, 2025Mar 25, 2026View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
36,979$0.98$36.2K36,979Mar 31, 2025Apr 2, 2025View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
38,74196,805Mar 26, 2024Mar 28, 2024View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
58,06458,064Mar 24, 2023Mar 28, 2023View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
236,220236,220Aug 11, 2022Aug 15, 2022View →
BDTX
BLACK DIAMOND THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
60,00060,000Feb 17, 2021Feb 19, 2021View →
BDTX
BLACK DIAMOND THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,00010,000Sep 8, 2020Sep 10, 2020View →
BDTX
BLACK DIAMOND THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000150,000Sep 8, 2020Sep 10, 2020View →
Other insiders · PYXS
Loading peer insiders…
About this filer
CIK 0001579781
ROLE
Director
PRIMARY
PYXS
COMPANIES
2
ACTIVE SINCE
Sep 2020
MARKETPEEL · /INSIDER/0001579781DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback